LPGO — Lipigon Pharmaceuticals AB Income Statement
0.000.00%
- SEK32.87m
- SEK8.87m
- SEK32.81m
Annual income statement for Lipigon Pharmaceuticals AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | SAS | SAS | SAS | SAS | SAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3.48 | 8.02 | 4.42 | 0 | 32.8 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 13.5 | 24.2 | 86.8 | 75.5 | 57.6 |
Operating Profit | -9.97 | -16.1 | -82.4 | -75.5 | -24.7 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -19.9 | -16.1 | -82.2 | -75.4 | -24.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -39.9 | -16.1 | -82.2 | -75.4 | -24.3 |
Net Income Before Extraordinary Items | |||||
Net Income | -160 | -16.1 | -82.2 | -75.4 | -24.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -319 | -16.1 | -82.2 | -75.4 | -24.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -24 | -1.18 | -7.54 | -4.24 | -0.378 |
Dividends per Share |